MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$401,251K
Net Income
-$4,890K
Net Profit Margin
-1.22%
EPS
-$0.05
Unit: Thousand (K) dollars
Revenue Breakdown
US
Revenue From Contract With Custo...
Collaboration and other
Non Us
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenues
401,251
730,803
442,934
399,356
Cost of sales (excluding amortization of in-licensed rights)
149,385
108,768
398,708
150,775
Research and development
91,258
153,960
325,336
218,890
Selling, general and administrative
107,600
108,951
128,297
91,893
Restructuring charge
-
-
1,499
40,510
Litigation contingency charge
39,000
-
-
-
Amortization of in-licensed rights
717
691
677
677
Total cost and expenses
387,960
372,370
854,517
502,745
Operating income (loss)
13,291
358,433
-411,583
-103,389
Gain (loss) on debt extinguishment
-
-
155,475*
-138,613
Other (expense) income, net
-15,040
-15,259
-22,188
47,953
Gain from sale of priority review voucher
-
-
0*
-
Total other (gain) income, net
-
-
133,287
-90,660
(loss) income before income tax expense (benefit)
-1,749
343,174
-278,296
-194,049
Income tax expense (benefit)
3,141
12,215
4,551
-14,102
Net (loss) income
-4,890
330,959
-282,847
-179,947
Unrealized gains on investments, net of tax
-
-
-
271
Total other comprehensive income
-
-
-
271
Comprehensive (loss) income
-
-
-
-179,676
Basic EPS
-0.05
3.15
-2.699
-1.8
Diluted EPS
-0.05
2.88
-2.94
-1.8
Basic Average Shares
105,431,000
104,988,000
104,876,000
100,237,000
Diluted Average Shares
105,431,000
121,916,000
96,258,000
100,237,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
US
$198,605K
Non Us
$31,959K
Revenue From Contract
With Customer...
$98,125K
Pmo Products
$230,564K
Elevidys
$98,125K
Products, net
$328,689K
(-35.94%↓ Y/Y)
Collaboration and other
$72,562K
(-25.93%↓ Y/Y)
Net (loss) income
-$4,890K
(-102.48%↓ Y/Y)
Total revenues
$401,251K
(-34.34%↓ Y/Y)
Income tax expense
(benefit)
$3,141K
(107.26%↑ Y/Y)
(loss) income before
income tax expense...
-$1,749K
(-101.14%↓ Y/Y)
Operating income (loss)
$13,291K
(-88.50%↓ Y/Y)
Total cost and
expenses
$387,960K
(-21.71%↓ Y/Y)
Other (expense)
income, net
-$15,040K
(-139.52%↓ Y/Y)
Cost of sales
(excluding amortization of...
$149,385K
(-2.08%↓ Y/Y)
Selling, general and
administrative
$107,600K
(-21.97%↓ Y/Y)
Research and development
$91,258K
(-55.35%↓ Y/Y)
Litigation contingency
charge
$39,000K
Amortization of in-licensed
rights
$717K
(7.50%↑ Y/Y)
Buy us a coffee
logo (1) copy-svg
Sarepta Therapeutics, Inc. (SRPT)
logo (1) copy-svg
Sarepta Therapeutics, Inc. (SRPT)